Latest news with #Andreas
Hamilton Spectator
23-07-2025
- Business
- Hamilton Spectator
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari, Andreas and Caroline will report to Ipsen's Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading the commercial operations for the International Region at Ipsen, Mari Scheiffele will now lead all medicines in Oncology and Rare Disease at Ipsen. In the new role, Mari will focus on driving product development and pipeline innovation for new medicines and lead globally, brands and life cycle management. Mari succeeds Bartek Bednarz who will now lead the newly created Asia, Pacific & China region at Ipsen. Andreas Gerber joins Ipsen from Johnson & Johnson where he most recently served as Worldwide Vice-president and Head of the Oncology Franchise. In his new role as Head of International, Andreas will lead Ipsen's operations in all geographies excluding North America. Andreas's extensive business acumen and commercial operations experience will support driving growth in Ipsen's three therapeutic areas: Oncology, Rare Disease and Neuroscience across the International region. Andreas succeeds Mari Scheiffele. Finally, Caroline Sitbon has been promoted to the role of Ipsen's General Counsel. Caroline joined the company from GSK in 2024 as Senior Vice President, Legal Affairs. In her new role, Caroline will lead legal and business ethics and will also serve as the Board of Directors' General Secretary. Caroline succeeds François Garnier who will be retiring after a very successful career, including his tenure as Ipsen's General Counsel and General Secretary to the Board of Directors. 'These three appointments bring additional highly qualified global leaders to our executive leadership team and I'm delighted that they represent a combination of internal promotions and new leaders that have joined Ipsen,' said David Loew, Chief Executive Officer. 'After personally working with both Mari and Caroline throughout their tenure at Ipsen, I have been impressed by their leadership, business insights and innovative mindsets. Each of these leaders, in their respective fields, have strongly contributed and partnered with Executive Leadership Team members to the ongoing transformation that we have been successfully driving at Ipsen. I am also very pleased to welcome Andreas to Ipsen. Over the last few years, I have observed his accomplishments and am convinced that his leadership and capacity to inspire our teams to execute and deliver on our strategy will be instrumental in our continuous growth trajectory in those respective markets. These additions also now represent a gender-balanced Executive Committee at Ipsen. I would also like to warmly thank François Garnier who had a long and distinguished career at Ipsen, making a big impact on the development of our company.' Mari Scheiffele said, 'I am honored to step into the role of Chief Product Officer at such an exciting time for our company. I am committed to driving innovation, fostering a culture of excellence, and continuing to work with our teams to deliver impact for our customers and patients.' Andreas Gerber said, 'I am thrilled to join Ipsen to lead the International Region and to work, together, with a world-class team to make a real impact on patients' everyday lives. I am looking forward to driving our innovative medicines across the portfolio to create access and adoption for patients and customers worldwide and to realize the full potential of our transformative therapies.' Caroline Sitbon added, 'It is an honor to take the General Counsel and General Secretary role and be part of this dynamic and fast-growing organization committed to advancing science for patients and consumers. I am very excited to have the opportunity to lead a highly qualified team that ensures our commitment to remain unwavering in compliance and integrity'. ABOUT IPSEN We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit . IPSEN CONTACTS Investors Khalid Deojee +33 6 66 01 95 26 Media Sally Bain +1 857 32 00 517 Anne Liontas +33 6 69 09 12 96 Disclaimers and/or Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on Attachment
Business Upturn
23-07-2025
- Business
- Business Upturn
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele is appointed to EVP, Chief Product Officer is appointed to Andreas Gerber is appointed to EVP, Head of International is appointed to Caroline Sitbon is appointed to EVP, General Counsel Mari, Andreas and Caroline will report to Ipsen's Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading the commercial operations for the International Region at Ipsen, Mari Scheiffele will now lead all medicines in Oncology and Rare Disease at Ipsen. In the new role, Mari will focus on driving product development and pipeline innovation for new medicines and lead globally, brands and life cycle management. Mari succeeds Bartek Bednarz who will now lead the newly created Asia, Pacific & China region at Ipsen. Andreas Gerber joins Ipsen from Johnson & Johnson where he most recently served as Worldwide Vice-president and Head of the Oncology Franchise. In his new role as Head of International, Andreas will lead Ipsen's operations in all geographies excluding North America. Andreas's extensive business acumen and commercial operations experience will support driving growth in Ipsen's three therapeutic areas: Oncology, Rare Disease and Neuroscience across the International region. Andreas succeeds Mari Scheiffele. Finally, Caroline Sitbon has been promoted to the role of Ipsen's General Counsel. Caroline joined the company from GSK in 2024 as Senior Vice President, Legal Affairs. In her new role, Caroline will lead legal and business ethics and will also serve as the Board of Directors' General Secretary. Caroline succeeds François Garnier who will be retiring after a very successful career, including his tenure as Ipsen's General Counsel and General Secretary to the Board of Directors. 'These three appointments bring additional highly qualified global leaders to our executive leadership team and I'm delighted that they represent a combination of internal promotions and new leaders that have joined Ipsen,' said David Loew, Chief Executive Officer. 'After personally working with both Mari and Caroline throughout their tenure at Ipsen, I have been impressed by their leadership, business insights and innovative mindsets. Each of these leaders, in their respective fields, have strongly contributed and partnered with Executive Leadership Team members to the ongoing transformation that we have been successfully driving at Ipsen. I am also very pleased to welcome Andreas to Ipsen. Over the last few years, I have observed his accomplishments and am convinced that his leadership and capacity to inspire our teams to execute and deliver on our strategy will be instrumental in our continuous growth trajectory in those respective markets. These additions also now represent a gender-balanced Executive Committee at Ipsen. I would also like to warmly thank François Garnier who had a long and distinguished career at Ipsen, making a big impact on the development of our company.' Mari Scheiffele said, 'I am honored to step into the role of Chief Product Officer at such an exciting time for our company. I am committed to driving innovation, fostering a culture of excellence, and continuing to work with our teams to deliver impact for our customers and patients.' Andreas Gerber said, 'I am thrilled to join Ipsen to lead the International Region and to work, together, with a world-class team to make a real impact on patients' everyday lives. I am looking forward to driving our innovative medicines across the portfolio to create access and adoption for patients and customers worldwide and to realize the full potential of our transformative therapies.' Caroline Sitbon added, 'It is an honor to take the General Counsel and General Secretary role and be part of this dynamic and fast-growing organization committed to advancing science for patients and consumers. I am very excited to have the opportunity to lead a highly qualified team that ensures our commitment to remain unwavering in compliance and integrity'. ABOUT IPSEN We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit . IPSEN CONTACTS Investors Khalid Deojee [email protected] +33 6 66 01 95 26 Media Sally Bain [email protected] +1 857 32 00 517 Anne Liontas [email protected] +33 6 69 09 12 96 Disclaimers and/or Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on Attachment Ipsen PR_ELT Changes_23072025 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Daily Mirror
17-07-2025
- Daily Mirror
Extreme sports influencer falls 600ft to death into Italian Dolomites ravine crash
Extreme sports influencer Andreas Tonelli, 48, is believed to have crashed his mountain bike moments before he plummeted 600ft into a ravine in the Italian Dolomites An extreme sports influencer has died after tragically crashing his bike and plummeting 600ft into a ravine. Andreas Tonelli's family raised the alarm on Tuesday evening after he failed to return home from a ride in the Italian Dolomites, sparking a huge helicopter search at around 9pm. His body was found in a ravine in the Vallunga area of Val Gardena three hours later, and was recovered the following morning. Authorities believe he plummeted from the mountain into the ravine below after a bicycle accident. Tonelli, 48, had 127,000 followers on Instagram, where he regularly shared videos of his daring trips on his mountain bike. One recent video showed him perilously clambering across a rock face using a wire to pull himself across with his bicycle on his back. In 2014, he left what he described as his "boring office job" to become a full-time bike guide. He had been organising bike trips since 2003, including routes across Italy, throughout Europe, and eventually all over the world. Mr Tonelli was also known to be a keen photographer, hiker and climber, and had proudly spoken of his bicycle climb of the active volcano Nevado Ojos de Salado in Chile. Among his feats was the completion of the L'Onda di Hokusai ('Hokusai Wave'), a route in the Dolomites made up nearly entirely of frozen mountaintop, and a successful scaling of the Tupungato volcano in central Chile. The accident on Tuesday unfolded in the Vallunga area of the Italian Dolomites as he tackled a difficult section alone. Just moments before the fatal fall, he posted an Instagram story showing himself smiling at the summit. Andreas was born in the tiny village of Völs am Schlern, at the foot of the Schlern mountain. In a recent comment about his love for travelling, he wrote: "But since I spend seven months a year travelling, I also call home all the other places in the world where I feel happy and free." Tributes have flooded in from within the European mountain biking community, with many speaking of him as an inspirational figure in the sport Outdoor clothing manufacturer Norrona, who Mr Tonelli worked with as a brand ambassador, wrote on Facebook: "Andreas was a passionate, dedicated, and important voice within the Norrøna family. "We will remember his big smile and his deep love for mountain biking, for nature, and for the friendships forged out there. Not only did he take part in testing and developing new Norrøna products, Andreas also worked as a bike guide for Norrøna Adventure — sharing his passion for mountain biking with every guest he met. "He made a profound impression on everyone fortunate enough to meet him. Our heartfelt thoughts and deepest condolences go out to his family and friends." One person commenting on the post described him "one of the most inspiring people in the hike and bike adventure scene", while another recalled meeting him on a trail in Norway and described him as a "good person".
Local Germany
04-07-2025
- Politics
- Local Germany
The most common names of unemployment money recipients in Germany
The most common names of unemployment ( Bürgergeld ) recipients are Michael, Andreas and Thomas. That's the result of an inquiry put forward to the Bundestag by the anti-immigrant Alternative for Germany (AfD) party, according to an exclusive report by the Rheinische Post. "Presumably, the party hoped for something different," the authors of the report wrote. The official inquiry read: "What are the 14 most common first names of recipients of the citizen's allowance ( Bürgergeld )...and how many people accounted for these first names?" The answer, given by Parliamentary State Secretary in the Federal Ministry of Labour and Social Affairs, Katja Mast (SPD), included the following figures: Michael - 19,200 Bürgergeld recipients as of June 2025 Andreas - 16,200 Thomas -15,700 Daniel - 14,800 Olena - 14,400 Alexander - 13,800 Ahmad - 13,700 Ali - 13,500 Christian - 13,400 Mohammad - 12,500 Anna - 12,400 Oleksandr - 12,000 Tetiana - 11,400 Iryna - 10,600 The Federal Employment Agency is cited as the source of the statistics. Seeking fodder for xenophobia If instead of a number of common German names at the top of the list, it was primarily foreign names in the top positions, then it can be assumed that the results of the inquiry would have been immediately announced by members of the AfD. The anti-immigration party regularly promotes unfounded narratives that people with a migrant background are detrimental to German society, including the claim that they are more often dependent on benefits like Bürgergeld - an idea which is proven to be inaccurate by their latest inquiry. Advertisement Members of the Bundestag often bring specific inquiries to try and highlight specific issues in German society. READ ALSO: Scandal-hit AfD politician makes comeback in German Bundestag German intelligence suspends AfD 'extremist' label amid appeal Citizen's allowance Bürgergeld , often translated as citizen's allowance, is a cash benefit for citizens and some residents in Germany who have no income or do not earn enough money to support themselves and their dependents - in other words, an unemployment benefit. As of February this year, 5.54 million people in Germany received the benefit. The black-red coalition of the Union and the SPD would like to reform the benefit to save money. Currently it costs the state around €50 billion euros a year.
Tom's Guide
01-07-2025
- Entertainment
- Tom's Guide
Netflix drops first trailer for new monster movie sequel — and it already looks like a colossal hit
Netflix just released the first teaser trailer for its upcoming monster sequel 'Troll 2,' and it looks like this follow-up to the popular original is taking a 'bigger is better' approach. Consider me sold. 'Troll' hit Netflix in December 2022 and became the streaming service's most-watched non-English language movie, having amassed more than 103 million views to date. A sequel was practically inevitable, and after a few years of waiting, we've finally got a glimpse of it. Netflix labels this a 'teaser', and that's very much the case. The brief trailer is little more than a minute long, but serves as a great mood-setter, and gives us an early look at some of the movie's main players, before ending on a juicy preview of a troll vs troll showdown. 'Godzilla vs. Kong' better watch out, as there's a new titan duo on the scene. The sequel will see several returning cast members, including Ine Marie Wilmann as Nora, Kim Falck as Andreas, and Mads Sjøgård Pettersen returning as army major Kristoffer. Plus, Roar Uthaug is back in the director's chair, so the sequel is retaining its key creative talent. 'Troll 2' is set to arrive on Netflix on December 1, and while it might not be the most traditional streaming pick for the holiday season, I can't wait to see how it unfolds. While our first look at 'Troll 2' may be relatively brief, Netflix has also released new details for the upcoming sequel via Tudum. For starters, we've got an insight into the movie's plot, which promises the core team's most 'perilous mission yet.' Get instant access to breaking news, the hottest reviews, great deals and helpful tips. In 'Troll 2,' Nora, Andreas and Kristoffer are forced into action when a new skyscraper-sized troll awakens and goes on a destructive rampage. With the clock ticking and the monster's path of carnage growing, they face seemingly impossible odds to stop the devastation before it's too late. While it hardly sounds like the most innovative sequel, instead opting to stick to the same path trodden by its predecessor, with a movie like 'Troll 2', really all viewers want is a massive monster smashing thing into the ground below their gigantic feet. And 'Troll 2' looks set to deliver exactly that, so who needs originality when you have titans causing total mayhem? 'With the sequel, we are aiming high - expanding the scope, deepening the story, and creating a troll-sized spectacle like you've never seen before. I cannot wait for fans to experience the adventure we have in store,' said Roar Uthaug. Alongside the returning stars and director, 'Troll 2' is also written by Espen Aukan (who penned the first movie), and Espen Horn and Kristian Strand Sinkerud are back as producers. As for fresh faces, Sara Khorami is joining the cast as newcomer Marion. The first 'Troll' was well-received by critics and holds an impressive 90% score on Rotten Tomatoes. However, while it was very popular on Netflix, taking the No. 1 spot in both the U.S. and U.K., not all the audience reactions were positive. The movie holds a 50% viewer score on the review aggregate site, suggesting some subscribers weren't so impressed. Either way, 'Troll 2' looks like a monster movie that is going to dominate the streaming landscape when it arrives this winter, and I can't wait to see these larger-than-life creatures return to Netflix. Remember, 'Troll 2' will begin streaming on Netflix globally on December 1. Meanwhile, if winter feels very far away (though with how quickly 2025 is speeding by, the holidays will be here before you know it), here's everything you can watch on Netflix in July 2025.
